Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Corporation Skyrocketed 23.9% in August

By Todd Campbell – Updated Sep 3, 2018 at 1:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-moving data for its only commercial-stage drug is on deck.

What happened

Ahead of long-term outcomes data from its cardiovascular outcomes study of Vascepa in September, Amarin Corporation plc (AMRN -2.60%) shares increased by 23.9% in August, according to S&P Global Market Intelligence.

So what

Vascepa is a purified fish-oil pill that won FDA approval in 2012 to lower triglycerides in patients with very high triglyceride levels.

A man in a suit with rockets attached to his back shoots skyward.


The company's sales of Vascepa have been hamstrung by the lack of proof that lowering triglyceride levels can directly reduce the likelihood of a major cardiovascular event, such as heart attack, stroke, or death. Yet Vascepa's revenue has been growing steadily, and in the second quarter, Amarin reported revenue of $52.6 million, up 16.4% year over year.

Earlier this year, Amarin reported that the final patient visit has occurred in its six-year outcomes study, and on Aug. 26, management said that the study is on track for "top-line results before the end of September 2018."

Now what

The stakes are high for Amarin. If its outcomes study is a success, then Vascepa could win considerably greater use, because there are roughly 3.8 million Americans with triglyceride levels of 500 to 2,000 mg/dl. Alternatively, if the trial fails, then sales could dwindle, casting a shadow over Amarin's future. Although sales have been climbing, Amarin lost $68 million on revenue of $181 million in 2017.

Overall, Vascepa's trial could go either way, and the binary nature of the trial and resulting impact on the company's financial condition means this stock is only suitable for aggressive and risk-tolerant investors.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.